Search Results - "FEIN, LUIS"

ATTITUDES AND BELIEFS OF ARGENTINIAN MEDICAL ONCOLOGISTS REGARDING PALLIATIVE CARE REFERRAL.

Alternate Title: Actitudes y creencias de los médicos oncólogos argentinos sobre la derivación a cuidados paliativos.

Authors: SALA, RAÚL A. DRAN, GRACIELA BRUERA, EDUARDO et al.

Source: Medicina (Buenos Aires). ene/feb2023, Vol. 83 Issue 1, p10-18. 9p. 1 Diagram, 2 Charts, 1 Graph.

Subjects: CANCER treatment, CANCER patients, ONCOLOGISTS, HEALTH surveys, QUALITY of life

Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.

Authors: Fein, Luis Lazaretti, Nicolas Chuken, Yamil López et al.

Source: Clinical Drug Investigation. Sep2023, Vol. 43 Issue 9, p699-706. 8p.

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.

Authors: Kowalyszyn, Ruben D. Fein, Luis E. Richardet, Martin E. et al.

Source: JCO Global Oncology. 3/24/2022, Vol. 8, p1-8. 8p.

Correction: Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2− Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate.

Authors: Fein, Luis Lazaretti, Nicolas Chuken, Yamil López et al.

Source: Clinical Drug Investigation. Sep2023, Vol. 43 Issue 9, p707-708. 2p.

Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer

Authors: Pereira, Jose R. Fein, Luis del Giglio, Auro et al.

Source: Lung Cancer (01695002). Oct2007, Vol. 58 Issue 1, p80-87. 8p.

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

Authors: Fizazi, Karim Tran, NamPhuong Fein, Luis et al.

Source: Lancet Oncology. May2019, Vol. 20 Issue 5, p686-700. 15p.

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors: Fizazi, Karim Namphuong Tran Fein, Luis et al.

Source: New England Journal of Medicine. 7/27/2017, Vol. 377 Issue 4, p352-360. 9p. 2 Charts, 2 Graphs.

Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).

Authors: Rapoport, Bernardo Chua, Daniel Poma, Allen et al.

Source: Supportive Care in Cancer. Nov2015, Vol. 23 Issue 11, p3281-3288. 8p.

Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study

Authors: Matsubara, Nobuaki Chi, Kim N. Özgüroğlu, Mustafa et al.

Source: European Urology. Apr2020, Vol. 77 Issue 4, p494-500. 7p.

Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.

Authors: Barrios, Carlos H. Hernandez-Barajas, David Brown, Michael P. et al.

Source: Cancer (0008543X). Mar2012, Vol. 118 Issue 5, p1252-1259. 8p.

Activity of ixabepilone in oestrogen receptor-negative and oestrogen receptor-progesterone receptor-human epidermal growth factor receptor 2-negative metastatic breast cancer

Authors: Pivot, Xavier B. Li, Rubi K. Thomas, Eva S. et al.

Source: European Journal of Cancer. Nov2009, Vol. 45 Issue 17, p2940-2946. 7p.

SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials.

Authors: Borrego MR Lu YS Reyes-Cosmelli F et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2024 Nov; Vol. 208 (1), pp. 111-121. Date of Electronic Publication: 2024 Aug 23.

Publication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.

Authors: Menzies AM Long GV Kohn A et al.

Source: Neuro-oncology advances [Neurooncol Adv] 2024 Mar 18; Vol. 6 (1), pp. vdae033. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE

A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis.

Authors: Menzies AM Long GV Kohn A et al.

Source: Future oncology (London, England) [Future Oncol] 2025 Jun; Vol. 21 (14), pp. 1703-1711. Date of Electronic Publication: 2025 May 26.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE; In Process

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

Authors: Choueiri TK Powles T Albiges L et al.

Corporate Authors: Choueiri TK Powles T Albiges L et al.

Source: The New England journal of medicine [N Engl J Med] 2023 May 11; Vol. 388 (19), pp. 1767-1778.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N Engl J Med Subsets: MEDLINE

Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer.

Authors: Rugo HS Umanzor GA Barrios FJ et al.

Corporate Authors: Rugo HS Umanzor GA Barrios FJ et al.

Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2023 Jan 01; Vol. 41 (1), pp. 65-74. Date of Electronic Publication: 2022 Jul 20.

Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

Authors: Gómez HL Neciosup S Tosello C et al.

Source: Clinical breast cancer [Clin Breast Cancer] 2016 Feb; Vol. 16 (1), pp. 38-44. Date of Electronic Publication: 2015 Nov 10.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE

Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

Authors: Buzaid AC Mathias Cde C Perazzo F et al.

Source: Clinical colorectal cancer [Clin Colorectal Cancer] 2010 Dec; Vol. 9 (5), pp. 282-9.

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes.

Authors: Hortobagyi GN Gomez HL Li RK et al.

Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2010 Jul; Vol. 122 (2), pp. 409-18. Date of Electronic Publication: 2010 May 08.

Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE

Planning cancer control in Latin America and the Caribbean.

Authors: Goss PE Lee BL Badovinac-Crnjevic T et al.

Source: The Lancet. Oncology [Lancet Oncol] 2013 Apr; Vol. 14 (5), pp. 391-436.

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE